Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Konkret geht es um den Diabetes-Patienten mit kardiovaskulären Erkrankungen oder Risiken, die Herzinsuffizienz sowie die kardiovaskuläre Primär- und Sekundärprävention. Sind Sie hier schon auf dem neuesten Stand? Unsere Experten beleuchten, wo und warum das bisherige Procedere geändert werden soll und was in der Praxis sinnvoll ist. Holen Sie sich Ihr Update und 2 CME-Punkte beim MMW-Webinar am 24. April von 17.30 bis 19 Uhr. 
Erweiterte Suche
Anmelden
nach oben
Diabetologia
Erschienen in: Diabetologia 1/2009

01.01.2009 | Consensus Statement Update

Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy

A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes

verfasst von: D. M. Nathan, J. B. Buse, M. B. Davidson, E. Ferrannini, R. R. Holman, R. Sherwin, B. Zinman

Erschienen in: Diabetologia | Ausgabe 1/2009

Einloggen, um Zugang zu erhalten

Abstract

The consensus algorithm for the medical management of type 2 diabetes was published in August 2006 with the expectation that it would be updated, based on the availability of new interventions and new evidence to establish their clinical role. The authors continue to endorse the principles used to develop the algorithm and its major features. We are sensitive to the risks of changing the algorithm cavalierly or too frequently, without compelling new information. An update to the consensus algorithm published in January 2008 specifically addressed safety issues surrounding the thiazolidinediones. In this revision, we focus on the new classes of medications that now have more clinical data and experience.
Literatur
1.
American Diabetes Association. Standards of medical care in diabetes (2008) Diabetes Care 31(Suppl 1):S12–S54
2.
European Diabetes Policy Group (1999) A desk-top guide to type 2 diabetes mellitus. Diabet Med 16:716–730CrossRef
3.
4.
Diabetes Control and Complications Trial Research Group (1993) The effect of intensive diabetes treatment on the development and progression of long-term complications in insulin-dependent diabetes mellitus: the Diabetes Control and Complications Trial. N Engl J Med 329:978–986
5.
Reichard P, Nilsson B-Y, Rosenqvist U (1993) The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med 329:304–309PubMedCrossRef
6.
UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complication in patients with type 2 diabetes (UKPDS 33). Lancet 352:837–853CrossRef
7.
UK Prospective Diabetes Study (UKPDS) Group (1998) Effect of intensive blood glucose control with metformin on complication in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352:854–865CrossRef
8.
Ohkubo Y, Kishikawa H, Araki E et al (1995) Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with NIDDM: A randomized prospective 6-year study. Diab Res Clin Pract 28:103–117CrossRef
9.
Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group (2003) Intensive diabetes therapy and carotid intima–media thickness in type 1 diabetes. N Engl J Med 348:2294–2303CrossRef
10.
Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group (2005) Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Eng J Med 353:2643–2653CrossRef
11.
The Action to Control Cardiovascular Risk in Diabetes Study Group (2008) Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358:2545–2559CrossRef
12.
The ADVANCE Collaborative Group (2008) Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358:2560–2572CrossRef
13.
14.
Nathan DM (2007) Finding new treatments for diabetes—how many, how fast … how good? N Engl J Med 356:437–440PubMedCrossRef
15.
Nathan DM (2002) Initial management of glycemia in type 2 diabetes mellitus. N Engl J Med 347:1342–1349PubMedCrossRef
16.
Sheehan MT (2003) Current therapeutic options in type 2 diabetes mellitus: a practical approach. Clin Med Res 1:189–200PubMedCrossRef
17.
18.
Klein R, Klein BEK, Moss SE, Davis MD, DeMets DL (1988) Glycosylated hemoglobin predicts the incidence and progression of diabetic retinopathy. JAMA 260:2864–2871PubMedCrossRef
19.
Chase HP, Jackson WE, Hoops SL, Cockerham RS, Archer PG, O’Brien D (1989) Glucose control and the renal and retinal complications of insulin-dependent diabetes. JAMA 261:1155–60PubMedCrossRef
20.
Little RR, Rohlfing CL, Wiedmeyer H-M, Myers GL, Sacks DB, Goldstein DE (2001) The National Glycohemoglobin Standardization Program (NGSP): a five year progress report. Clin Chem 47:1985–1992PubMed
21.
Grundy SM, Cleeman JI, Merz NB et al (2004) Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110:227–239PubMedCrossRef
22.
Chobanian AV, Bakris GL, Black HR et al (2003) National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation and Treatment Of High Blood Pressure; National High blood Pressure Education Program Coordinating committee. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment Of High Blood Pressure: the JNC 7 report. JAMA 289:2560–2572PubMedCrossRef
23.
DCCT Research Group (1995) The association between glycemic exposure and long-term diabetic complications in the Diabetes Control and Complications Trial. Diabetes 44:968–983CrossRef
24.
Stratton IM, Adler AI, Neil HA et al (2000) Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321:405–412PubMedCrossRef
25.
National Institutes of Health (1999) Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. The Evidence Report. National Heart, Lung, and Blood Institute, NIH, Bethesda, MD
26.
27.
28.
Malaisse WJ (2003) Pharmacology of the meglitinide analogs: new treatment options for type 2 diabetes mellitus. Treat Endocrinol 2:401–414PubMedCrossRef
29.
Van de Laar FA, Lucassen PL, Akkermans RP et al (2005) Alpha-glucosidase inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2:CD003639
30.
31.
32.
Drucker DJ (2005) Biologic actions and therapeutic potential of the proglucagon-derived peptides. Nature Endocrinol Metab 1:22–31CrossRef
33.
Schmitz O, Brock B, Rungby J (2004) Amylin agonists: a novel approach in the treatment of diabetes. Diabetes 53(Suppl 3):S233–238PubMedCrossRef
34.
Richter B, Bandeira-Echtler E, Bergerhoff K, Lerch C (2008) Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. Cochrane Database Syst. Rev. 2:CD006739
35.
Amori RE, Lau J, Pittas AG (2007) Efficacy and safety of incretin therapy in type 2 diabetes: a systematic review and meta-analysis. JAMA 298:194–206PubMedCrossRef
36.
Monami M, Lamannac C, Marchionni N, Mannucci E (2008) Comparison of different drugs as add-on treatments to metformin in type 2 diabetes: a meta-analysis. Diabetes Res Clin Pract 79:196–203PubMedCrossRef
37.
Bolen S, Feldman L, Vassy J et al (2007) Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med 147:386–399PubMed
38.
Colagiuri S, Cull CA, Holman RR, UKPDS Group (2002) Are lower fasting plasma glucose levels at diagnosis of type 2 diabetes associated with improved outcomes?: UK Prospective Diabetes Study 61. Diabetes Care 25:1410–1417PubMedCrossRef
39.
Harris MI (1991) Epidemiologic correlates of NIDDM in Hispanics, whites and blacks in the U.S. population. Diabetes Care 14(Suppl 3):639–648CrossRef
40.
Rewers M, Hamman RF (1995) Risk factors for non-insulin dependent diabetes. In: Harris M (ed) Diabetes in America, 2nd ed. NIH Publication No. 95–1468. National Institutes of Health, Bethesda, pp 179–220
41.
Look AHEAD Research Group (2007) Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the Look AHEAD trial. Diabetes Care 30:1374–1383CrossRef
42.
Pories WJ, Swanson MS, MacDonald KG et al (1995) Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann Surg 222:339–350PubMedCrossRef
43.
Sjostrom L, Lindroos AK, Peltonen M, Swedish Obese Subjects Study Scientific Group et al (2004) Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 351:2683–2693PubMedCrossRef
44.
Dixon JB, O’Brien PE, Playfair J et al (2008) Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. JAMA 299:316–323PubMedCrossRef
45.
Pontiroli AE, Folli F, Paganelli M et al (2005) Laparoscopic gastric banding prevents type 2 diabetes and arterial hypertension and induces their remission in morbid obesity: a 4-year case–controlled study. Diabetes Care 28:2703–2709PubMedCrossRef
46.
Diabetes Prevention Program Research Group (2005) Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care 28:888–894CrossRef
47.
Hadden DR, Montgomery DAD, Skelly RJ et al (1975) Maturity onset diabetes mellitus: response to intensive dietary management. BMJ 3:276–278PubMed
48.
Peters AL, Davidson MB (1996) Maximal dose glyburide in markedly symptomatic patients with type 2 diabetes: a new use for an old friend. J Clin Endocrinol Metab 81:2423PubMedCrossRef
49.
DeFronzo R, Goodman A (1995) Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med 333:541–549PubMedCrossRef
50.
Diabetes Prevention Program Research Group (2002) Reduction in incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393–403CrossRef
51.
Salpeter S, Greyber E, Pasternak G, Salpeter E (2006) Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst. Rev. 1:CD002967PubMed
52.
Shaw JS, Wilmot RL, Kilpatrick ES (2007) Establishing pragmatic estimated GFR thresholds to guide metformin prescribing. Diabetic Medicine 24:1160–1163PubMedCrossRef
53.
Holstein A, Plaschke A, Egberts E-H (2001) Lower incidence of severe hypoglycemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide. Diabetes Metab Res Rev 17:467–473PubMedCrossRef
54.
Gangji AS, Cukierman T, Gerstein HC, Goldsmith CH, Clase CM (2007) A systematic review and meta-analysis of hypoglycemia and cardiovascular events: a comparison of glyburide with other secretagogues and with insulin. Diabetes Care 30:389–94PubMedCrossRef
55.
Kahn SE, Haffner SM, Heise MA, ADOPT Study Group et al (2006) Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355:2427–2443PubMedCrossRef
56.
Meinert CL, Knatterud GL, Prout TE, Klimt CR (1970) The University Group Diabetes Program: a study of the effect of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II Mortality results. Diabetes 19(Suppl 1):789–830
57.
Rosenstock J, Hassman DR, Madder RD et al (2004) Repaglinide versus nateglinide monotherapy: a randomized, multicenter study. Diabetes Care 27:1265–1270PubMedCrossRef
58.
Gerich J, Raskin P, Jean-Louis L, Purkayastha D, Baron A (2005) PRESERVE-beta: two year efficacy and safety of initial combination therapy with nateglinide or glyburide plus metformin. Diabetes Care 28:2093–2099PubMedCrossRef
59.
Damsbo P, Clauson P, Marbury TC, Windfeld K (1999) A double blind randomized comparison of meal-related glycemic control by repaglinide and glyburide in well-controlled type 2 diabetic patients. Diabetes Care 22:789–794PubMedCrossRef
60.
Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M (2003) Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM Trial. JAMA 290:486–494PubMedCrossRef
61.
Home PD, Pocock SJ, Beck-Nielsen H, RECORD Study Group et al (2007) Rosiglitazone evaluated for cardiovascular outcomes—an interim analysis. N Engl J Med 357:28–38PubMedCrossRef
62.
Singh S, Loke YK, Furberg CD (2007) Thiazolidinediones and heart failure: a teleoanalysis. Diabetes Care 30:2248–2254CrossRef
63.
Khan MA, St Peter JV, Xue JL (2002) A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone. Diabetes Care 25:708–711PubMedCrossRef
64.
Goldberg RB, Kendall DM, Deeg MA, GLAI Study Investigators et al (2005) A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 28:1547–1554PubMedCrossRef
65.
Nissen SE, Wolski K (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356:2457–2471PubMedCrossRef
66.
Singh S, Loke YK, Furberg CD (2007) Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 298:1189–1195PubMedCrossRef
67.
Dormandy JA, Charbonnel B, Eckland DJA et al (2005) Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive (PROspective pioglitAzone Clinical Trial in macrovascular Events): a randomized controlled trial. Lancet 366:1279–1289PubMedCrossRef
68.
Lincoff AM, Wolski K, Nicholls SJ, Nissen SE (2007) Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 298:1180–1188PubMedCrossRef
69.
Nathan DM, Buse JB, Davidson MB et al (2008) Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Update regarding the thiazolidinediones. Diabetologia 51:8–11
70.
Meier C, Kraenzlin ME, Bodmer M, Jick SS, Jick H, Meier CR (2008) Use of thiazolidinediones and fracture risk. Arch Intern Med 168:820–825PubMedCrossRef
71.
Horvath K, Jeitler K, Berghold A et al (2007) Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. Cochrane Database Syst Rev 2:CD005613PubMed
72.
Raskin P, Allen E, Hollander P (2005) Initiating insulin therapy in type 2 diabetes. Diabetes Care 28:260–265PubMedCrossRef
73.
Dailey G, Rosenstock J, Moses RG, Ways K (2004) Insulin glulisine provides improved glycemic control in patients with type 2 diabetes. Diabetes Care 27:2363–2368 80PubMedCrossRef
74.
Nathan DM, Roussell A, Godine JE (1988) Glyburide or insulin for metabolic control in non-insulin-dependent diabetes mellitus: a randomized double-blind study. Ann Int Med 108:334–340PubMed
75.
Abraira C, Johnson N, Colwell J, VA CSDM Group (1995) VA Cooperative study on glycemic control and complications in type II diabetes. Diabetes Care 18:1113–1123PubMedCrossRef
76.
77.
Miller CD, Phillips LS, Ziemer DC, Gallina DL, Cook CB, El-Kebbi IM (2005) Hypoglycemia in patients with type 2 diabetes mellitus. Arch Int Med 161:1653–1659CrossRef
78.
Kendall DM, Riddle MC, Rosenstock J et al (2005) Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 28:1083–1091PubMedCrossRef
79.
DeFronzo RA, Ratner RE, Han J et al (2005) Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 28:1092–1100PubMedCrossRef
80.
Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD (2005) Exenatide-113 Clinical Study Group. Effects of exenatide on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 27:2628–35CrossRef
81.
Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG (2005) Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes. Ann Int Med 143:559–569PubMed
82.
Riddle M, Frias J, Zhang B et al (2007) Pramlintide improved glycemic control and reduced weight in patients with type 2 diabetes using basal insulin. Diabetes Care 30:2794–2799PubMedCrossRef
83.
Raz I, Hanefeld M, Xu L, Caria C, Davies M, Williams-Herman D (2006) Sitagliptin Study 023 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 49:2564–2571PubMedCrossRef
84.
Goldstein B, Feinglos M, Lunceford J, Johnson J, Williams-Herman D (2007) Sitagliptin 036 Study Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care 30:1979–1987PubMedCrossRef
85.
Welschen LMC, Bloemendal E, Nijpels G et al (2005) Self-monitoring of blood glucose in patients with type 2 diabetes who are not using insulin: a systematic review. Diabetes Care 28:1510–1517PubMedCrossRef
86.
Farmer A, Wade A, Goyder E et al (2007) Impact of self monitoring of blood glucose in the management of patients with non-insulin treated diabetes: open parallel group randomised trial. BMJ 335:132PubMedCrossRef
87.
Ilkova H, Glaser B, Tunckale A, Bagriacik N, Cerasi E (1997) Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment. Diabetes Care 20:1353–1356PubMedCrossRef
88.
Weng J, Li Y, Xu W et al (2008) Effect of intensive insulin therapy on beta-cell function and glycemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomized parallel-group trial. Lancet 371:1753–1760PubMedCrossRef
89.
UKPDS Group (1995) UK Prospective Diabetes Study 16: overview of six years’ therapy of type 2 diabetes: a progressive disease. Diabetes 44:1249–1258CrossRef
90.
Hirsch IB, Bergenstal RM, Parkin CG, Wright E, Buse JB (2005) A real-world approach to insulin therapy in primary care practice. Clinical Diabetes 23:78–86CrossRef
91.
Schwartz S, Sievers R, Strange P, Lyness WH, Hollander P (2003) Insulin 70/30 mix plus metformin versus triple oral therapy in the treatment of type 2 diabetes after failure of two oral drugs. Diabetes Care 26:2238–2243PubMedCrossRef
92.
Yki-Jarvinen H, Ryysy L, Nikkila K, Tulokas T, Vanamo R, Heikkila M (1999) Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. Ann Int Med 130:389–396PubMed
Metadaten
Titel
Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy
A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes
verfasst von
D. M. Nathan
J. B. Buse
M. B. Davidson
E. Ferrannini
R. R. Holman
R. Sherwin
B. Zinman
Publikationsdatum
01.01.2009
Verlag
Springer-Verlag
Erschienen in
Diabetologia / Ausgabe 1/2009
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-008-1157-y

Weitere Artikel der Ausgabe 1/2009

Diabetologia 1/2009 Zur Ausgabe

Letter

Predicting the outcome of islet isolation in large mammals

For Debate

Preventing hypoglycaemia: what is the appropriate glucose alert value?

Article

Anti-angiogenic factors and pre-eclampsia in type 1 diabetic women

Article

Insulin sensitivity measured by the euglycaemic insulin clamp and proinsulin levels as predictors of stroke in elderly men

Article

The association of common genetic variants in the APOA5, LPL and GCK genes with longitudinal changes in metabolic and cardiovascular traits

Article

Trends in cardiovascular admissions and procedures for people with and without diabetes in England, 1996–2005

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

24.04.2024 | DGIM 2024 | Nachrichten

Bei Senioren mit Prostatakarzinom auf Anämie achten!

23.04.2024 | Ablationstherapie | Nachrichten

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 | Prävention und Rehabilitation in der Kardiologie | Nachrichten

Europäische Ernährungsgewohnheiten: Das sind die häufigsten Fehler

23.04.2024 | Appendizitis | Nachrichten

Hinter dieser Appendizitis steckte ein Erreger
weitere anzeigen

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise